HORIZON (OP-106) study of melflufen in patients with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab and/or pomalidomide: Updated efficacy and safety Meeting Abstract


Authors: Richardson, P. G.; Oriol, A.; Larocca, A.; Otero, P. R.; Norkin, M.; Bladé, J.; Cavo, M.; Hassoun, H.; Leleu, X.; Alegre, A.; Maisel, C.; Paner, A.; Mazumder, A.; Zonder, J. A.; Puig, N.; Harran, J.; Harmenberg, J.; Thuresson, S.; Zubair, H.; Mateos, M. V.
Abstract Title: HORIZON (OP-106) study of melflufen in patients with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab and/or pomalidomide: Updated efficacy and safety
Meeting Title: 7th Annual Meeting of the Society of Hematologic Oncology (SOHO 2019)
Keywords: multiple myeloma; phase 2; pomalidomide; mm; daratumumab; melflufen
Journal Title: Clinical Lymphoma, Myeloma and Leukemia
Volume: 19
Issue: Suppl. 1
Meeting Dates: 2019 Sep 11-14
Meeting Location: Houston, TX
ISSN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2019-09-01
Start Page: S329
End Page: S330
Language: English
ACCESSION: WOS:000483480700351
DOI: 10.1016/j.clml.2019.07.318
PROVIDER: wos
Notes: Meeting Abstract: MM-250 -- Source: Wos
Altmetric Score
MSK Authors
  1. Hani Hassoun
    151 Hassoun
Related MSK Work